1.Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2000;30:1144-50.
2. Johnston SL, Unsworth J, Gompels MM. Adrenaline given outside the context of life threatening allergic reactions. BMJ 2003;326:589-90.
3. McLean-Tooke AP, Bethune CA, Fay AC, Spickett GP. Adrenaline in the treatment of anaphylaxis: what is the evidence? BMJ 2003;327:1332-5.
4. Simons FE, Ardusso LR, Bilo MB, et al. World allergy organization guidelines for the assessment and management of anaphylaxis. The World Allergy Organization journal 2011;4:13-37.
5. Gallagher M, Worth A, Cunningham-Burley S, Sheikh A. Epinephrine auto-injector use in adolescents at risk of anaphylaxis: a qualitative study in Scotland, UK. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 2011;41:869-77.
6. Gold MS, Sainsbury R. First aid anaphylaxis management in children who were prescribed an epinephrine autoinjector device (EpiPen). The Journal of allergy and clinical immunology 2000;106:171-6.
7. Chipps BE. Update in Pediatric Anaphylaxis: A Systematic Review. Clinical pediatrics 2013.
8. Campbell RL, Manivannan V, Hartz MF, Sadosty AT. Epinephrine auto-injector pandemic. Pediatric emergency care 2012;28:938-42.
9. Haute Autorité de Santé H. Epipen (adrénaline auto-injectable). In.
Étude et pratique
HTA : quelle PA cible chez les patients à haut risque cardiovasculaire ?
Mise au point
Troubles psychiatriques : quand évoquer une maladie neurodégénérative ?
Étude et pratique
Complications de FA, l’insuffisance cardiaque plus fréquente que l’AVC
Cas clinique
L’ictus amnésique idiopathique